Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 13/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465300 | 1.00 | ACHE (0.57) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL7090295 | 0.98 | ACHE (0.54) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL12340557 | 0.87 | ACHE (0.57) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL6468825 | 0.81 | ACHE (0.57) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL6469045 | 0.81 | ACHE (0.57) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL23854313 | 0.80 | TDP1 (0.62) | CA12CA1CA2CA9ACLY | |
| SCHEMBL26192235 | 0.80 | ACHE (0.55) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL26192228 | 0.80 | ACHE (0.59) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL6467953 | 0.79 | ACHE (0.54) | ACHEEPHX2CA12CA1CA2 | |
| SCHEMBL25220742 | 0.75 | ACHE (0.89) | ACHEEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236212-A1 | Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses | ESPERION THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236212-A1 | Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses | ACADM, COASY, ACACA | ACHE 584/4885EPHX2 1300/4885CA12 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.